Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes

Clinical Editorial

This secondary analysis of a randomized clinical trial evaluates the effect of oral semaglutide on heart failure events, major adverse cardiovascular events, and safety among participants with or without heart failure at baseline.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis

Pharmacology • 17 Aug 2026

Finerenone Slows eGFR Decline in Chronic Kidney Disease Patients Without Diabetes

General • 06 Aug 2026

Endocrine NewsRelated by Conditiondiabetesheart failure

Moving Forward: The Future of GLP-1 Therapies

Endocrinology • 11 Mar 2026

Endocrine NewsRelated by Conditiondiabetesheart failure

Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes

Endocrinology • 17 Feb 2026

Med News TodayRelated by Conditiondiabetessemaglutide

GLP-1 Drugs May Help Reduce Lung Scarring After COVID

Research Highlights • 12 Jul 2026